A non-comparative, randomized phase II study of two different oral schedules of gimatecan (ST1481) as second line therapy for patients with advanced Non Small Cell Lung Cancer (NSCLC)

Registry ID

EUCTR2004-001043-30

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE2

Sponsor

SIGMA-TAU

Start date

2004-10-18

Last update

2026-08-16

Conditions

• Advanced Non Small Cell Lung Cancer (NSCLC)

Summary

Advanced Non Small Cell Lung Cancer (NSCLC)

Locations

• , , Italy

Related clinical trials

• A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer
• Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers

View on source registry